Neurogastrx: $60M crossover round to advance de-risked GI assets

A June deal that came together through Vivo Capital brought a Phase III-ready asset into the hands of Neurogastrx, complementing an existing gastrointestinal program and an executive team with experience in the disease space from its members’ time at Ironwood.

Vivo led a $60 million crossover series B round that positions Neurogastrx Inc. for continued clinical work on the two programs, while its newly hired CFO could soon be tasked with taking the company public...